Skip to main content

Advertisement

SpringerLink
Log in

The Role of Chemical Sphincterotomy with Urethral Botulinum Toxin Injection in Patients with Neurogenic and Non-neurogenic Failure to Empty

  • Neurogenic Bladder (C Powell, Section Editor)
  • Published:
Current Bladder Dysfunction Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

This review focuses on the evidence for injection of botulinum A toxin (BTX) to the external urinary sphincter for management of impaired bladder emptying secondary to neurogenic conditions such as detrusor sphincter dyssynergia (DSD) and non-neurogenic conditions such as dysfunctional voiding (DV). The application of urethral BTX for patients with impaired emptying secondary to detrusor underactivity will also be discussed. The goal of the review is to comprehensively analyze the evidence surrounding urethral BTX in this context and help guide decision-making.

Recent Findings

A robust body of literature including case series, a randomized control trial (RCT), and a meta-analysis support the use of urethral BTX for the treatment of DSD in spinal cord injury (SCI) patients, with documented improvement in urethral pressure and post-void residual urine volume (PVR). A second RCT among patients with DSD and MS demonstrated no improvement in urethral pressure, PVR, or maximum urine flow rate following urethral BTX relative to control. For non-neurogenic conditions like DV and pelvic floor spasticity, there are mixed data regarding the efficacy of urethral BTX. Small series have reported improvement in PVR and urethral pressure, but a RCT in this patient population demonstrated no benefit of urethral BTX relative to control.

Summary

Urethral BTX effectively lowers urethral pressure and PVR in SCI patients with DSD, though the long-term impact on renal function requires further study. For patients with MS and those with non-neurogenic conditions like DV, pelvic floor spasticity, and detrusor under activity, the role of urethral BTX is not well defined. Further study in these patient populations should be undertaken prior to widespread utilization.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major Importance

  1. Lapides J, Diokno AC, Silber SJ, Lowe BS. Clean, intermittent self-catheterization in the treatment of urinary tract disease. J Urol. 1972;107(3):458–61.

    Article  PubMed  CAS  Google Scholar 

  2. Ross JC, Damanski M, Gibbon N. Resection of the external urethral sphincter in the paraplegic; preliminary report. J Urol. 1958 Apr;79(4):742–6.

    Article  PubMed  CAS  Google Scholar 

  3. • Moore D, Cohn J, Dmochowski R. Use of botulinum toxin A in the treatment of lower urinary tract disorders: a review of the literature. Toxins. 2016;8(4):88. This thorough and detailed review article provides an overview of the mechanism of action of botulinum toxin and applications in the lower urinary tract

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Leippold T, Reitz A, Schurch B. Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Urol. 2003 Aug;44(2):165–74.

    Article  PubMed  CAS  Google Scholar 

  5. Cruz F. Targets for botulinum toxin in the lower urinary tract: targets for botulinum toxin. Neurourol Urodyn. 2014 Jan;33(1):31–8.

    Article  PubMed  CAS  Google Scholar 

  6. Schurch B, Hauri D, Rodic B, Curt A, Meyer M, Rossier AB. Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol. 1996 Mar;155(3):1023–9.

    Article  PubMed  CAS  Google Scholar 

  7. •• Mehta S, Hill D, Foley N, Hsieh J, Ethans K, Potter P, et al. A meta-analysis of botulinum toxin sphincteric injections in the treatment of incomplete voiding after spinal cord injury. Arch Phys Med Rehabil. 2012;93(4):597–603. This meta-analysis pools all available data on urethral botulinum toxin in the spinal cord injury patient population, providing the highest level of evidence available for this clinical application.

    Article  PubMed  Google Scholar 

  8. Kuo H-C. Effect of botulinum a toxin in the treatment of voiding dysfunction due to detrusor underactivity. Urology. 2003;61(3):550–4.

    Article  PubMed  Google Scholar 

  9. Kuo H-C. Botulinun A toxin urethral sphincter injection for neurogenic or nonneurogenic voiding dysfunction. Tzu Chi Med J. 2016;28(3):89–93.

    Article  Google Scholar 

  10. Tsai S-J, Ying T-H, Huang Y-H, Cheng J-W, Bih L-I, Lew HL. Transperineal injection of botulinum toxin A for treatment of detrusor sphincter dyssynergia: localization with combined fluoroscopic and electromyographic guidance. Arch Phys Med Rehabil. 2009 May;90(5):832–6.

    Article  PubMed  Google Scholar 

  11. Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol. 1988 May;139(5):919–22.

    Article  PubMed  CAS  Google Scholar 

  12. Soler JM, Previnaire JG, Hadiji N. Predictors of outcome for urethral injection of botulinum toxin to treat detrusor sphincter dyssynergia in men with spinal cord injury. Spinal Cord. 2016 Jun;54(6):452–6.

    Article  PubMed  CAS  Google Scholar 

  13. Kuo H-C. Satisfaction with urethral injection of botulinum toxin A for detrusor sphincter dyssynergia in patients with spinal cord lesion. Neurourol Urodyn. 2008 Nov;27(8):793–6.

    Article  PubMed  CAS  Google Scholar 

  14. de Sèze M, Petit H, Gallien P, de Sèze M-P, Joseph P-A, Mazaux J-M, et al. Botulinum a toxin and detrusor sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur Urol. 2002 Jul;42(1):56–62.

    Article  PubMed  Google Scholar 

  15. • Gallien P. Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. J Neurol Neurosurg Psychiatry. 2005;76(12):1670–6. This randomized control trial assessed urethral botulinum toxin for treating DSD in patients with MS found no benefit to treatment, raising doubts regarding the use of urethral BTX in MS patients.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Wein A, Barrett DM. Etiologic possibilities for increased pelvic floor electromyography activity during cystometry. J Urol. 1982;127(5):949–51.

    Article  PubMed  CAS  Google Scholar 

  17. Chen YH, Kuo H-C. Botulinum A toxin treatment of urethral sphincter pseudodyssynergia in patients with cerebrovascular accidents or intracranial lesions. Urol Int. 2004;73(2):156–62.

    Article  PubMed  CAS  Google Scholar 

  18. •• Mangera A, Andersson K-E, Apostolidis A, Chapple C, Dasgupta P, Giannantoni A, et al. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol. 2011;60(4):784–95. This systematic review article provides an overview of the efficacy of botulinum toxin in the lower urinary tract, including urethral BTX, with detailed complication data.

    Article  PubMed  CAS  Google Scholar 

  19. Smith CP, Nishiguchi J, O’Leary M, Yoshimura N, Chancellor MB. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology. 2005;65(1):37–41.

    Article  PubMed  Google Scholar 

  20. Liao Y-M, Kuo H-C. Causes of failed urethral botulinum toxin A treatment for emptying failure. Urology. 2007;70(4):763–6.

    Article  PubMed  Google Scholar 

  21. Phelan MW, Franks M, Somogyi GT, Yokoyama T, Fraser MO, Lavelle JP, et al. Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol. 2001;165(4):1107–10.

    Article  PubMed  CAS  Google Scholar 

  22. Mokhless I, Gaafar S, Fouda K, Shafik M, Assem A. Botulinum A toxin urethral sphincter injection in children with nonneurogenic neurogenic bladder. J Urol. 2006 Oct;176((4):1767–70.

    Article  CAS  Google Scholar 

  23. Kuo H-C. Recovery of detrusor function after urethral botulinum a toxin injection in patients with idiopathic low detrusor contractility and voiding dysfunction. Urology. 2007 Jan;69(1):57–61.

    Article  PubMed  Google Scholar 

  24. • Jiang Y-H, Wang C-C, Kuo H-C. OnabotulinumtoxinA urethral sphincter injection as treatment for non-neurogenic voiding dysfunction—a randomized, double-blind, placebo-controlled study. Sci Rep [Internet]. 2016 Dec [cited 2018 Apr 17];6(1). Available from: http://www.nature.com/articles/srep38905. This randomized control trial demonstrates no benefit of urethral BTX compared to placebo in treatment of non-neurogenic patients, raising doubts about the application urethral BTX to this patient population.

  25. Chancellor MB, Bennett C, Simoneau AR, Finocchiaro MV, Kline C, Bennett JK, et al. Sphincteric stent versus external sphincterotomy in spinal cord injured men: prospective randomized multicenter trial. J Urol. 1999;161(6):1893–8.

    Article  PubMed  CAS  Google Scholar 

  26. Gajewski JB, Chancellor MB, Ackman CF, Appell RA, Bennett J, Binard J, et al. Removal of UroLume endoprosthesis: experience of the North American Study Group for detrusor-sphincter dyssynergia application. J Urol. 2000;163(3):773–6.

    Article  PubMed  CAS  Google Scholar 

  27. Wilson TS, Lemack GE, Dmochowski RR. UroLume stents: lessons learned. J Urol. 2002;167(6):2477–80.

    Article  PubMed  Google Scholar 

  28. Hamid R, Arya M, Wood S, Patel HRH, Shah PJR. The use of the Memokath™ stent in the treatment of detrusor sphincter dyssynergia in spinal cord injury patients: a single-centre seven-year experience. Eur Urol. 2003;43(5):539–43.

    Article  PubMed  CAS  Google Scholar 

  29. Minardi D, d’Anzeo G, Parri G, Polito M, Piergallina M, El Asmar Z, et al. The role of uroflowmetry biofeedback and biofeedback training of the pelvic floor muscles in the treatment of recurrent urinary tract infections in women with dysfunctional voiding: a randomized controlled prospective study. Urology. 2010;75(6):1299–304.

    Article  PubMed  Google Scholar 

  30. Datta SN, Chaliha C, Singh A, Gonzales G, Mishra VC, Kavia RBC, et al. Sacral neurostimulation for urinary retention: 10-year experience from one UK centre. BJU Int. 2008;101(2):192–6.

    PubMed  Google Scholar 

  31. Jonas U, Fowler CJ, Chancellor MB, Elhilali MM, Fall M, Gajewski JB, et al. Efficacy of sacral nerve stimulation for urinary retention: results 18 months after implantation. J Urol. 2001 Jan;165(1):15–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Section of Urology, University of Chicago Medicine, 5841 S. Maryland Ave. MC 6038, Chicago, IL, 60637, USA

    William R. Boysen & Gregory T. Bales

Authors
  1. William R. Boysen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gregory T. Bales
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William R. Boysen.

Ethics declarations

Conflict of Interest

William Boysen and Gregory Bales have no relevant conflicts of interest to disclose.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Neurogenic Bladder

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Boysen, W.R., Bales, G.T. The Role of Chemical Sphincterotomy with Urethral Botulinum Toxin Injection in Patients with Neurogenic and Non-neurogenic Failure to Empty. Curr Bladder Dysfunct Rep 13, 162–168 (2018). https://doi.org/10.1007/s11884-018-0478-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11884-018-0478-z

Keywords

Search

Navigation